Program launched in 2022 has grown into a global pipeline partner for academic teams, awarding approximately $2.48 million in 2025 to projects in the U.S., Europe and Australia

TUCSON, Ariz. , Sept. 4, 2025 /PRNewswire/ -- Critical Path Institute® (C-Path) announced today that its Translational Therapeutics Accelerator (TRxA) program has completed a record year of funding and mentorship, making seven BRIDGe awards to academic drug-development teams. TRxA launched in 2022 and awarded its first grants in 2023. In 2025 the program supported seven projects, its largest annual cohort.

The 2025 portfolio spans high-need diseases and multiple modalities. Awards include:

$473,000 to Stan van de Graaf , M.D., Ph.D. (Amsterdam UMC) and Matthias Versele , Ph.D. (KU Leuven's CD3) f

See Full Page